Opinion Article - Journal of Orthopedic Surgery and Rehabilitation (2023) Volume 7, Issue 4

Precision medicine and personalized approaches in orthopaedic oncology

Kurt Goodman^*

Department of Orthopaedic Surgery

*Corresponding Author:

Kurt Goodman
Department of Orthopaedic Surgery
Hardvard University
USA
E-mail:kurt@goodman.edu

Received:28-Jun-2023,Manuscript No. AAOSR-23- 105162; Editor assigned:01-Jul-2023,PreQC No. AAOSR-23- 105162(PQ); Reviewed:15-Jul-2023,QC No. AAOSR-23- 105162; Revised:20-Jul-2023,Manuscript No. AAOSR-23- 105162(R); Published:27-Jul-2023,DOI: 10.35841/ aaosr-7.4.156

Citation: Kurt Goodman.Precision medicine and personalized approaches in orthopaedic oncology.J Ortho Sur Reh.2023;7(4):156

Abstract

Introduction

Orthopaedic oncology has been transformed by precision medicine and personalised treatments that adapt treatment plans to each patient depending on their particular characteristics. Orthopaedic oncology is concerned with the diagnosis, therapy, and management of bone and soft tissue tumours, which frequently pose difficult problems because of the heterogeneity of the tumours, their varied aggressiveness, and the wide range of patient treatment reactions. By tailoring medications based on unique tumour characteristics, genetic profiles, and patient considerations, precision medicine promises to improve results. Next-generation sequencing and gene expression profiling are two examples of modern molecular profiling techniques that have made it possible to gain previously unheard-of insights into the genomic changes and molecular markers connected to orthopaedic tumours.[1].

With the aid of these techniques, scientists and medical professionals may pinpoint certain genetic mutations, chromosomal rearrangements, and gene expression patterns that fuel the development and spread of tumours. Precision medicine enables targeted medicines that directly suppress aberrant signalling pathways or exploit tumour weaknesses by knowing the molecular landscape of individual tumours, resulting in more effective and less harmful treatments. Age, general health status, comorbidities, and treatment preferences are only a few of the patient-related factors taken into account by orthopaedic oncology personalised techniques.[2].

For treatment planning and outcome optimisation, specific patient features such bone quality, functional needs, and psychological variables are taken into account. The most effective surgical method, evaluating whether neoadjuvant or adjuvant medicines are required, and taking into account reconstructive choices that maximise functional outcomes and quality of life are all examples of personalised approaches.[3].

Precision medicine and personalised strategies are especially important in orthopaedic oncology because of the heterogeneity of tumours, the possibility of limb-sparing surgery, and the effect of treatment on patients' mobility and usefulness. Orthopaedic oncologists are able to pinpoint important molecular targets, forecast treatment outcomes, and personalise patient care plans by combining thorough genetic analysis, cutting-edge imaging tools, and interdisciplinary teamwork. Additionally, the development of novel therapeutics such targeted pharmacological therapies, immunotherapies, and regenerative medicine strategies holds enormous promise thanks to precision medicine and personalised approaches.[4].

Researchers can find novel therapeutic targets and create specialised therapies that maximise treatment success while minimising side effects by understanding the precise molecular changes driving tumour growth. The implementation of precision medicine and personalised treatment strategies in orthopaedic oncology still faces several obstacles, such as the requirement for validated biomarkers, accessibility to cutting-edge molecular profiling tools, and the integration of various clinical data for well-informed decision-making. To overcome these obstacles and bring the promise of precision medicine into clinical practise, collaboration among researchers, physicians, and industry partners is crucial.[5].

Conclusion

In conclusion, there are great possibilities for enhancing outcomes in orthopaedic oncology thanks to precision medicine and personalised strategies. Clinicians can improve treatment selection, forecast treatment responses, and improve patient outcomes by utilising genetic profiling, molecular characterization, and specific patient characteristics. Precision medicine will become more crucial in directing personalised treatment decisions as our knowledge of tumour biology and therapeutic targets advances. This will ultimately improve the prognosis and quality of life for people with orthopaedic tumours.

References

1. Lurie JM, Png CM, Subramaniam S,et al.Virchow’s triad in “silent” deep vein thrombosis. Journal of Vascular Surgery J VascSurg Venous Lymphat Disord.2019;7(5):640-5.

Indexed at, Google Scholar, Cross Ref

2. Falck-Ytter Y, Francis CW, Johanson NA,et al.Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest.2012;141(2):e278S-325S.

Indexed at, Google Scholar, Cross Ref

3. Shi S,Cheng J,Chen H,et al..Preoperative and intraoperative predictors of deep venous thrombosis in adult patients undergoing craniotomy for brain tumors: A Chinese single-center, retrospective study. Thromb Res.2020; 196:245-50.

Indexed at, Google Scholar, Cross Ref

4. Hazeltine MD, Guber RD, Buettner H,et al.Venous thromboembolism risk stratification in trauma using the Caprini risk assessment model. Thromb Res.2021;208:52-7.

Indexed at, Google Scholar, Cross Ref

5. Ishida T, Shibahashi K, Sugai S,et al.Development of a risk stratification scoring system for deep vein thrombosis upon psychiatric admission.J Psychosom Res.2021; 147:110540.

Indexed at, Google Scholar, Cross Ref